Ovid Therapeutics Inc.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.3M
- Net income
- -$17.4M
- Total assets
- $150.9M
- Market cap
- $447.9M
- Operating margin
- -585.2%
- Net margin
- -240.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.3M
- Operating expenses
- $49.7M
- Operating income
- -$42.4M
- Income tax
- $0
- Net income
- -$17.4M
Balance sheet
- Total assets
- $150.9M
- Current assets
- $74.4M
- Total liabilities
- $20.3M
- Current liabilities
- $8.3M
- Shareholders’ equity
- $130.7M
Cash flow
- Operating cash flow
- -$38.3M
- Investing cash flow
- -$49.9M
- Financing cash flow
- $75.2M
- Net cash flow
- -$13.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $447.9M
- Shares outstanding
- 189.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 5, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.4M in FY2025.
- Revenue declined 97% from FY2021 to FY2025.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ovid Therapeutics Inc..
Write a review
News about Ovid Therapeutics Inc.
News & sentiment via Polygon.io
